Navigation Links
5 more pharmaceutical companies join NIH initiative to speed therapeutic discovery
Date:6/12/2012

Five additional pharmaceutical companies have joined a National Institutes of Health-led effort to help scientists research promising new treatments for patients. Funding and molecular compound information is available now for the initial phase of the recently unveiled Discovering New Therapeutic Uses for Existing Molecules program. This NIH-industry collaboration will match researchers with 58 compounds to test ideas for new therapeutic uses. Since the launch of the program last month, the total number of compounds the companies are making available has more than doubled.

Abbott, Bristol-Myers Squibb Company, GlaxoSmithKline, Janssen Pharmaceutical Research & Development, L.L.C., and Sanofi have joined Pfizer, AstraZeneca, and Eli Lilly and Company in this innovative approach to research.

The NIH's new National Center for Advancing Translational Sciences (NCATS) created the Therapeutics Discovery program to help re-engineer the research pipeline. By crowdsourcing compounds that already have cleared several key steps in the development process, including safety testing in humans, scientists nationwide have the opportunity to contribute their expertise to advancing these resources for new disease therapies.

The eight participating companies will provide their compounds and related data, which were determined by the NIH to meet specific eligibility criteria. For example, each compound must have advanced to clinical studies but been unsuccessful in its original therapeutic indication or not pursued for business reasons. Preliminary information about the compounds, including mechanism of action, route of administration, and any limitations in use based on safety and tolerability, are available at http://ncats.nih.gov/therapeutics-directory.html.

"Each company participating in this innovative collaboration has made substantial research and development investments to advance these compounds to the point where they can be used in clinical studies," said Kathy L. Hudson, Ph.D., NCATS acting deputy director. "If researchers funded through this effort can demonstrate new uses for the compounds, they could significantly reduce the amount of time it takes to get a treatment to patients in need."

For the pilot phase of the program, in fiscal year 2013, NCATS will provide up to $20 million to fund two- to three-year staged, cooperative agreement research grants. If specific milestones are met, funded researchers will conduct pre-clinical validation and clinical feasibility studies in the first stage, and proof-of-concept clinical trials in the second stage, to test whether one of the compounds may be effective against a previously unexplored disease target. The pilot phase also is intended to test the utility of the newly created template agreements by reducing the negotiation time that otherwise could delay the research.


'/>"/>

Contact: Bobbi Gardner
gardnerbw@mail.nih.gov
301-443-9919
NIH/National Center for Research Resources
Source:Eurekalert

Related medicine news :

1. Nobel laureate to keynote international pharmaceutical conference at URI
2. MSU invention could help pharmaceutical industry save money
3. Global, common approach to pharmaceutical supply chain integrity the focus of workshop
4. Georgia Tech launches HomeLab to help companies evaluate home health technologies
5. Kudos for 3 NJIT Enterprise Development Center high-tech companies
6. New initiative aims to increase mobility for disabled children worldwide
7. National initiative launched to change the way biology departments approach undergraduate education
8. Researchers creating designer lymph nodes based on Moffitts Total Cancer Care initiative
9. U.S. Spends Too Little on Public Health Initiatives: Report
10. Program to coordinate regional systems to speed heart attack care
11. Advanced genetic screening method may speed vaccine development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... February 27, 2017 , ... This webinar , sponsored ... a tool to characterize particle size distributions in the field of geoscience and ... novel scientific findings. It describes methods of optimized and standardized sample collection, preparation ...
(Date:2/27/2017)... ... February 27, 2017 , ... ... alcohol treatment programs in British Columbia, Canada, at https://www.sunshinecoasthealthcentre.ca/ , is proud ... The new hire, Mackenzie Alsager, showcases the Centre's commitment to innovation in drug ...
(Date:2/26/2017)... (PRWEB) , ... February 25, 2017 , ... The February ... Jong-un, heightened awareness and concern over nerve agents and the deadly use of chemical ... human nervous system and how even small doses can be lethal. , Jay Jagannathan, ...
(Date:2/26/2017)... York, New York (PRWEB) , ... February 26, ... ... luxury baby products for wholesale distribution in North America, today announced it would ... online sites. The company, which prides itself on crafting quality and unique baby ...
(Date:2/26/2017)... , ... February 26, 2017 , ... ... after receiving cognitive rehabilitation, according to a study released today at the 1st ... cognitive rehabilitation programs are proven to be effective in improving cognitive function in ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)...  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" ... on tissue protection, repair and regeneration, today announced ... received a positive response from the U.S. FDA ... RGN-137 to treat epidermolysis bullosa ("EB"). RGN-137 is ... beta 4 ("Tß4") as the active pharmaceutical ingredient. ...
(Date:2/27/2017)...  CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) ... Ph.D., as President and Chief Executive Officer (CEO) and member ... Craig succeeds Richard Love , interim President and CEO ... Directors.  Dr. Craig has over 20 years of experience in ... Europe . "On behalf of ...
(Date:2/24/2017)... Following receiving CE Marking in Europe ... AMAR is a major milestone for the country where the device was developed ... market in Israel   ... inclusion in the National Health Basket , Israel , ... E-QURE Corp. (OTCQB: EQUR), a leader in medical devices for the treatment of advanced wound ...
Breaking Medicine Technology: